Authors
Latest:
Dr. Al-Sawaf on the Benefit of Fixed-Duration Obinutuzumab/Venetoclax in CLLOthman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.
Latest:
Dr. O'Connor on Targeting CD30 in DLBCLOwen A. O'Connor, MD, PhD, professor of Medicine and Experiment Therapies, co-program director, Lymphoid Development and Malignancy Program, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses targeting CD30 expression in patients with diffuse large B-cell lymphoma.
Latest:
Dr. O'Connor on Recent FDA Approvals in MCLOwen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the recent FDA approval of acalabrutinib (Calquence) for patients with mantle cell lymphoma (MCL).
Latest:
Dr. O'Connor on Treatment Options Following Ibrutinib Progression in MCLOwen O'Connor, MD, PhD, professor of medicine and experimental therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses treatment options following progression on ibrutinib (Imbruvica) for patients with mantle cell lymphoma (MCL).
Latest:
Cosmo Smith on The Breakthrough Oncology Accelerator Flagship ProgramP. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses The Breakthrough Oncology Accelerator flagship program.
Latest:
Dr. Ferraro on the Use of Molecular Profiling in Pancreatic CancerPablo Ferraro, MD, discusses the use of molecular profiling in pancreatic cancer.
Latest:
Dr. Valderrabano on Understanding Cancer Risk in Indeterminate Thyroid NodulesPablo Valderrabano, MD, Clinical Research Fellow at Moffitt Cancer Center, discusses molecular markers in thyroid nodules and their connection to cancer incidence.
Latest:
Dr. Sharma Discusses Immune Checkpoint Resistance in GU CancersPadmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.
Latest:
Dr. Torka on BTK Inhibitors Available for Patients With R/R MCLPallawi Torka, MD, discusses the BTK inhibitors available for treatment of patients with relapsed/refractory mantle cell lymphoma.
Latest:
IV Calcium/Magnesium Has No Effect on Oxaliplatin-Induced NeuropathyIntravenous calcium plus magnesium given before or after adjuvant FOLFOX chemotherapy has absolutely no effect on the development of sensory neurotoxicity induced by oxaliplatin.
Latest:
Dr. Allen on Treatment Options in Advanced-Stage Hodgkin LymphomaPamela Blair Allen, MD, MSc, discusses treatment options in advanced-stage Hodgkin lymphoma.
Latest:
Dr. Kunz on the Importance of Tailoring Treatments to Patients With NETsPamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.
Latest:
Dr Kunz on Time to Response With Lutetium Lu 177 Dotatate in GEP-NETsPamela L. Kunz, MD, discusses a subanalysis of the NETTER-2 study investigating frontline lutetium Lu 177 dotatate in advanced, well-differentiated GEP-NETs.
Latest:
Dr. Munster on Vorinostat Plus Tamoxifen for Breast CancerPamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.
Latest:
Dr. Munster on Developing BiosimilarsPamela N. Munster, MD, professor, department of medicine (hematology/oncology), University of California, San Francisco (UCSF), director, early phase clinical trials unit, co-leader, Center for BRCA Research, leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the developmental process for biosimilars in oncology.
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology CareUSPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.
Latest:
Dr. Becker on the Rationale for Investigating Uproleselan in Combination with Chemotherapy in AMLPamela S. Becker, MD, PhD, discusses the rationale for investigating uproleselan in combination with chemotherapy in relapsed/refractory acute myeloid leukemia.
Latest:
Dr. Konstantinopoulos on the Phase III Results of the JAVELIN 200 Trial in Ovarian CancerPanagiotis A. Konstantinopoulos, MD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the disappointing results of the JAVELIN 200 trial in ovarian cancer.
Latest:
Dr. Konstantinopoulos on Immunotherapy in Ovarian CancerPanagiotis A. Konstantinopoulos, MD, PhD, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the role of immunotherapy in the treatment of patients with ovarian cancer.
Latest:
Dr. Savvides on the Risk of COVID-19 in Patients With CancerPanayiotis S. Savvides, MD, discusses COVID-19 precautions for patients with lung cancer.
Latest:
Dr. Ascierto on Choosing Combinations in Treatment of MelanomaPaolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how to choose between combination therapies in the treatment of patients with melanoma.
Latest:
Dr Ghia on Long-Term Efficacy With Acalabrutinib Monotherapy in CLLPaolo Ghia, MD, PhD, discusses long-term follow-up data from a pooled analysis evaluating the efficacy of acalabrutinib monotherapy in CLL.
Latest:
Examining the Importance of the Institutional Perspectives in Cancer WebinarsJason Porter, MD, Subramanian Janakiraman, MD, Natalie S. Calendar, MD, Parameswaran Hari, MD, MRCP, and Kevin Kalinsky, MD, MS, discuss the importance of the Institutional Perspectives in Cancer webinars.
Latest:
Narsoplimab Trial ResultsThe panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.
Latest:
Dr. Singh on Potential Implications of the IMvigor130 Trial in Bladder CancerParminder Singh, MD, discusses potential implications of the phase III IMvigor130 trial in advanced bladder cancer.
